UNSPSC 51292104: Maprotiline

This classification denotes an antidepressant agent with the molecular formula C20H23N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U1W68TROF, chemically known as 9,10-ethanoanthracene-9(10h)-propylamine, n-methyl- but generally known as maprotiline, which bears US NIH Compound Identifier 4011. European Medicines Agency schedules Maprotiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08647MIG.

UNSPSC 51292104 Maprotiline is a Commodity code that nominally describes a single tricyclic antidepressant drug product, yet recent state and local procurement activity under this code spans a much broader pharmaceutical and health-systems landscape: naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distributed through authorized wholesalers. The code sees solicitation from state health and human services agencies, county health departments, and multistate cooperative purchasing alliances. Issuing bodies range from single-county procurement offices (Seminole County, Florida) to statewide health authorities (Texas Health and Human Services Commission) and regional purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). These entities buy finished pharmaceutical products, OTC supplies, and pharmacy logistics services in volumes ranging from hundreds to potentially thousands of units annually, with delivery and compliance requirements that include FDA certification, cGMP adherence, supply-chain security, and insurance coverage.

Geographic activity centers on Florida, Texas, and Minnesota as recent solicitation hubs, with the MMCAP cooperative extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted Jun 30, 2026, due Jul 26, 2026) for 1,900 units of naloxone and 800 drug deactivation systems annually through quarterly deliveries; Texas HHS Commission's RFI HHS0017013 (posted Apr 3, 2026) exploring direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels; and Minnesota's MMCAP RFP S1070000015802 (posted Jan 20, 2026, due Mar 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers with awards effective July 1, 2026. Vendors in active competition face administrative fees, performance penalties, comprehensive insurance mandates, and FEMA or state-compliance overlay requirements. The code shows modest but steady activity in health-system procurement rather than concentration in a single product line or jurisdiction.